APP and Alzheimer disease: At the conclusion of the in vitro selection process, we selected four candidate compounds—NUCC-0226446, NUCC-0226614, NUCC-0226646, and NDC-1173 for in vivo evaluation in the APP/PS1 transgenic mouse model of AD.